Updates are available Correction dated 2022-02-07
Click to view Correction: https://doi.org/10.1186/s13063-022-06050-0
-
Authors
Pascoe, Elaine M.
Chadban, Steven J.
Fahim, Magid A.
Hawley, Carmel M.
Johnson, David W.
Collins, Michael G. http://orcid.org/0000-0003-2169-9087
,
-
Funding
Funding for this research was provided by:
Department of Health, Australian Government (APP1152390)
Health Research Council of New Zealand (17/414)
National Health and Medical Research Council (APP1092957)
Royal Australasian College of Physicians (Jacquot Research Establishment Award 2017)
Baxter Healthcare Corporation (Baxter Medication Delivery Grant 2017)
- License Information
-
More Information
Article History
Received: 24 August 2021
Accepted: 27 December 2021
First Online: 18 January 2022
Change Date: 7 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-022-06050-0
Declarations
:
: Ethics approval for the BEST-Fluids trial was obtained from the Northern A Health and Disability Ethics Committee (approval number 17/NTA/62), for New Zealand, and from the Sydney Local Health District Human Research Ethics Committee, Royal Prince Alfred Hospital (approval numbers X17–0201 and HREC/17/RPAH/308), for Australia. The study has received local governance approvals at each of the participating sites. Protocol amendments are submitted to and approved by the ethics committees prior to implementation. Written informed consent has been obtained from all participants in the study. For children, consent has been obtained from parents or guardians, with assent sought from adolescents and children where appropriate.
: Consent for publication is not applicable since there are no identifying images or other personal or clinical details of participants presented.
: MC has received research support from Baxter Healthcare Pty Ltd., the manufacturer of Plasmalyte, through a Baxter Investigator Initiated Research grant that provided fluids for this trial (commercial value of US $36,270). EP is an employee of the Sponsor, The University of Queensland. DJ has received consultancy fees, research grants, speaker’s honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from Astra Zeneca and AWAK, speaker’s honoraria and travel sponsorships from ONO, and BI & Lilly, and travel sponsorships from ONO and Amgen. CH has received research grants from Baxter and NHMRC related to the current project. The other authors declare that they have no competing interests.
